Therefore, the study investigated whether the inhibition of β-catenin protein favored a decrease in the expression of crucial angiogenesis-promoting factors, such as VEGF-A and MMP, in all treated breast cancer cell lines. This evidence concerns the gene VEGFA and breast carcinoma.